每月1针！安进AMG 133启动减重III期临床

医药魔方2025-03-06

3月5日，全球临床试验收录网站clinicaltrials显示，安进启动了AMG 133（Maridebart Cafraglutide，MariTide）的两项III期临床试验（MARITIME-1和MARITIME-2），标志着AMG 133进入III期开发阶段。MARITIME-1MARITIME-1是一项随机、双盲、安慰剂对照临床试验（n=3501），旨在评估AMG 133（低中高剂量）在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2517013632?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-06 16:50","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2517013632","market":"us","top_or_hot":-1,"title":"每月1针！安进AMG 133启动减重III期临床","media":"医药魔方","content":"<div>\n<p>3月5日，全球临床试验收录网站clinicaltrials显示，安进启动了AMG 133（Maridebart Cafraglutide，MariTide）的两项III期临床试验（MARITIME-1和MARITIME-2），标志着AMG 133进入III期开发阶段。MARITIME-1MARITIME-1是一项随机、双盲、安慰剂对照临床试验（n=3501），旨在评估AMG 133（低中高剂量）在...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165532abeb1222&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>每月1针！安进AMG 133启动减重III期临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n每月1针！安进AMG 133启动减重III期临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-06 16:50 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165532abeb1222&s=b><strong>医药魔方</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月5日，全球临床试验收录网站clinicaltrials显示，安进启动了AMG 133（Maridebart Cafraglutide，MariTide）的两项III期临床试验（MARITIME-1和MARITIME-2），标志着AMG 133进入III期开发阶段。MARITIME-1MARITIME-1是一项随机、双盲、安慰剂对照临床试验（n=3501），旨在评估AMG 133（低中高剂量）在...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165532abeb1222&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165532abeb1222&s=b","article_id":"2517013632","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165532abeb1222&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2517013632","pubTimestamp":1741251040,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月5日，全球临床试验收录网站clinicaltrials显示，安进启动了AMG 133的两项III期临床试验，标志着AMG 133进入III期开发阶段。MARITIME-2是一项随机、双盲、安慰剂对照临床试验，旨在评估AMG 133在伴2型糖尿病的肥胖或超重成人患者中的有效性、安全性和耐受性。AMG 133的降糖和减重效果已经在II期研究中得到了初步验证。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","LU0058720904.USD":"联博国际健康护理基金A","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","BK4566":"资本集团","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4505":"高瓴资本持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","AMG":"Affiliated Managers Group Inc","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4135":"资产管理与托管银行","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","AMGN":"安进","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4134":"信息科技咨询与其它服务","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4599":"减肥药","BK4581":"高盛持仓","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","III":"信息服务","LU0122379950.USD":"贝莱德世界健康科学A2","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓"},"translate_title":"1 needle per month! Amgen AMG 133 initiates phase III clinical trial for weight loss","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"AMG":1,"III":1},"content_text":"3月5日，全球临床试验收录网站clinicaltrials显示，安进启动了AMG 133（Maridebart Cafraglutide，MariTide）的两项III期临床试验（MARITIME-1和MARITIME-2），标志着AMG 133进入III期开发阶段。MARITIME-1MARITIME-1是一项随机、双盲、安慰剂对照临床试验（n=3501），旨在评估AMG 133（低中高剂量）在不伴2型糖尿病的肥胖或超重成人患者中的有效性、安全性和耐受性。研究的主要终点是第72周患者的体重相较于基线的百分比变化。MARITIME-2是一项随机、双盲、安慰剂对照临床试验（n=999），旨在评估AMG 133（低中高剂量）在伴2型糖尿病的肥胖或超重成人患者中的有效性、安全性和耐受性。研究的主要终点是第72周患者的体重相较于基线的百分比变化。AMG133是安进自主研发的一款注射频率可达到每4周1次的first-in-class抗体多肽偶联药物，由靶向葡萄糖依赖性促胰岛素释放多肽受体（GIPR）的全人源单抗偶联两个GLP-1类似物而成，通过抑制GIPR并激活GLP-1受体（GLP-1R）来发挥减少食物摄入和调节代谢进而减轻体重和降低血糖的作用。AMG 133的降糖和减重效果已经在II期研究中得到了初步验证。数据显示，经AMG 133（140/280/420mg）治疗52周后，不伴2型糖尿病的肥胖或超重成人患者（n=465，基线平均体重为107kg）的体重平均降幅达到20%，并且没有出现体重减轻平台期；伴2型糖尿病的肥胖或超重成人患者（n=127，基线平均体重为104kg，基线平均HbA1c水平为7.9%）的体重平均降幅为17%，同样没有出现体重减轻平台期，并且平均HbA1c水平降低了2.2%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517013632","isCrawlerRequest":true}